Table 5.
Univariate and multivariate predictors of overall survival
Univariate model | Multivariable model (stepwise) | ||||||
---|---|---|---|---|---|---|---|
Variables | Median OS (days) | 95% CI | p-value (Log-rank) | Hazard ratio | 95% CI | p-value | |
Gender | Female | 365 | 276-501 | 0.05 | |||
Male | 270 | 204-346 | |||||
Age | < 65 years | 325 | 271-400 | 0.81 | |||
≥ 65 years | 297 | 210-398 | |||||
Albumin | ≥ 35 g/L | 325 | 271-365 | 0.02 | |||
< 35 g/L | 54 | 42-408 | |||||
LDH | Normal | 366 | 320-501 | 0.001 | |||
Elevated | 210 | 147-276 | 1.75 | 1.24-2.46 | 0.001 | ||
No. of metastatic sites | ≤ 2 | 358 | 299-446 | 0.0001 | |||
> 2 | 210 | 136-290 | 1.68 | 1.18-2.40 | 0.004 | ||
ECOG Performance Status | 0 | 366 | 302-464 | 0.02 | |||
> 0 | 270 | 158-325 | 1.42 | 1.00-1.99 | 0.05 | ||
Hemoglobin | ≥ 12 g/dL | 350 | 273-412 | 0.09 | |||
< 12 g/dL | 276 | 185-346 | |||||
WBC | ≤ 10.5 × 109/L | 345 | 276-398 | 0.07 | |||
> 10.5 × 109/L | 236 | 103-352 | |||||
Platelets | ≤ 400 × 109/L | 329 | 273-398 | 0.23 | |||
> 400 × 109/L | 261 | 137-352 | |||||
Lymphocytes | ≥ 0.7 × 109/L | 346 | 290-400 | 0.04 | |||
< 0.7 × 109/L | 166 | 99-315 | |||||
Lung metastases | No | 338 | 271-414 | 0.58 | |||
Yes | 302 | 223-365 | |||||
Liver metastases | No | 366 | 297-501 | 0.01 | |||
Yes | 250 | 191-329 | |||||
Bone metastases | No | 329 | 276-365 | 0.32 | |||
Yes | 261 | 135-433 | |||||
Brain | No | 320 | 270-358 | 0.47 | |||
Yes | 269.5 | 40-499 | |||||
Peritoneal Mets | No | 325 | 250-365 | 0.99 | |||
Yes | 315 | 257-474 | |||||
No. of prior treatments | < 3 | 302 | 266-365 | 0.76 | |||
≥ 3 | 320 | 227-400 |
Abbreviations: LDH = lactate dehydrogenase; No. = number; ECOG = Eastern Cooperative Oncology Group; WBC = white blood cells; OS = overall survival; CI = confidence interval